Pemigatinib, the first therapy approved by the U.S. FDA for the treatment of advanced CCA patients with FGFR2 fusion and rearrangement positivity, demonstrated objective responses in 38 out of 146 enrolled patients (Liu et al., 2020). The gene discussed is FGFR2; the disease is cholangiocarcinoma.